Zhejiang Medicine Co., Ltd. (SHA:600216)
China
· Delayed Price · Currency is CNY 14.70
+0.09 (0.62%)
Apr 29, 2026, 3:00 PM CST
Zhejiang Medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 8,770 | 8,834 | 9,336 | 7,762 | 8,073 | 9,088 | Upgrade
|
| Other Revenue | 46.23 | 46.23 | 38.76 | 32.11 | 43.23 | 41.3 | Upgrade
|
| Revenue | 8,816 | 8,881 | 9,375 | 7,794 | 8,116 | 9,129 | Upgrade
|
| Revenue Growth (YoY) | -6.03% | -5.28% | 20.29% | -3.96% | -11.10% | 24.60% | Upgrade
|
| Cost of Revenue | 6,131 | 5,984 | 5,591 | 5,392 | 5,438 | 5,530 | Upgrade
|
| Gross Profit | 2,685 | 2,896 | 3,785 | 2,402 | 2,678 | 3,599 | Upgrade
|
| Selling, General & Admin | 1,403 | 1,409 | 1,678 | 1,481 | 1,312 | 1,546 | Upgrade
|
| Research & Development | 496.23 | 579.88 | 749.35 | 860.07 | 809.28 | 806.86 | Upgrade
|
| Other Operating Expenses | 44.07 | 51.37 | 53.85 | 52.3 | 69.86 | 75.17 | Upgrade
|
| Operating Expenses | 1,940 | 2,037 | 2,494 | 2,394 | 2,188 | 2,439 | Upgrade
|
| Operating Income | 745.4 | 859.52 | 1,291 | 7.98 | 489.74 | 1,160 | Upgrade
|
| Interest Expense | -24.82 | -24.82 | -26.37 | -28.34 | -33.11 | -39.54 | Upgrade
|
| Interest & Investment Income | 35.84 | 32.72 | 22.51 | 16.51 | 13.18 | 57.42 | Upgrade
|
| Currency Exchange Gain (Loss) | 74.97 | 74.97 | 17.82 | 36.59 | 66.6 | -64.31 | Upgrade
|
| Other Non Operating Income (Expenses) | -87.29 | -5.2 | 3.9 | 21.09 | -36.73 | -2.69 | Upgrade
|
| EBT Excluding Unusual Items | 744.1 | 937.2 | 1,308 | 53.83 | 499.67 | 1,111 | Upgrade
|
| Impairment of Goodwill | - | - | -18.68 | -9.23 | -8.12 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 6.13 | 4.64 | -29.6 | -28.59 | -56.51 | 51.73 | Upgrade
|
| Gain (Loss) on Sale of Assets | -4.24 | -6.56 | -5.21 | 323.57 | -1.37 | -7.95 | Upgrade
|
| Asset Writedown | 16.34 | -25.62 | -69.41 | - | - | -46.19 | Upgrade
|
| Other Unusual Items | 42.07 | 42.07 | 26.77 | 23.69 | 57.71 | 44.76 | Upgrade
|
| Pretax Income | 804.4 | 951.73 | 1,212 | 363.28 | 491.39 | 1,154 | Upgrade
|
| Income Tax Expense | 171.05 | 191.49 | 192.03 | 86.48 | 128.77 | 268.97 | Upgrade
|
| Earnings From Continuing Operations | 633.35 | 760.24 | 1,020 | 276.79 | 362.61 | 884.56 | Upgrade
|
| Minority Interest in Earnings | 117.96 | 113.14 | 140.26 | 152.85 | 176.96 | 160.76 | Upgrade
|
| Net Income | 751.31 | 873.38 | 1,161 | 429.64 | 539.57 | 1,045 | Upgrade
|
| Net Income to Common | 751.31 | 873.38 | 1,161 | 429.64 | 539.57 | 1,045 | Upgrade
|
| Net Income Growth | -48.54% | -24.74% | 170.11% | -20.37% | -48.38% | 45.71% | Upgrade
|
| Shares Outstanding (Basic) | 956 | 955 | 959 | 955 | 964 | 959 | Upgrade
|
| Shares Outstanding (Diluted) | 956 | 955 | 959 | 955 | 964 | 959 | Upgrade
|
| Shares Change (YoY) | 0.91% | -0.42% | 0.46% | -0.91% | 0.47% | 0.26% | Upgrade
|
| EPS (Basic) | 0.79 | 0.91 | 1.21 | 0.45 | 0.56 | 1.09 | Upgrade
|
| EPS (Diluted) | 0.78 | 0.91 | 1.21 | 0.45 | 0.56 | 1.09 | Upgrade
|
| EPS Growth | -49.30% | -24.79% | 168.89% | -19.64% | -48.62% | 45.33% | Upgrade
|
| Free Cash Flow | 1,207 | 1,439 | 534.15 | -162.56 | -455.39 | 197.05 | Upgrade
|
| Free Cash Flow Per Share | 1.26 | 1.51 | 0.56 | -0.17 | -0.47 | 0.20 | Upgrade
|
| Dividend Per Share | 0.280 | 0.280 | 0.370 | 0.150 | 0.170 | 0.330 | Upgrade
|
| Dividend Growth | -24.32% | -24.32% | 146.67% | -11.77% | -48.48% | 43.48% | Upgrade
|
| Gross Margin | 30.46% | 32.61% | 40.37% | 30.82% | 33.00% | 39.43% | Upgrade
|
| Operating Margin | 8.46% | 9.68% | 13.77% | 0.10% | 6.03% | 12.71% | Upgrade
|
| Profit Margin | 8.52% | 9.84% | 12.38% | 5.51% | 6.65% | 11.45% | Upgrade
|
| Free Cash Flow Margin | 13.69% | 16.21% | 5.70% | -2.09% | -5.61% | 2.16% | Upgrade
|
| EBITDA | 1,452 | 1,569 | 2,013 | 732.17 | 1,171 | 1,747 | Upgrade
|
| EBITDA Margin | 16.47% | 17.67% | 21.47% | 9.39% | 14.42% | 19.14% | Upgrade
|
| D&A For EBITDA | 706.83 | 709.85 | 721.94 | 724.19 | 680.81 | 586.79 | Upgrade
|
| EBIT | 745.4 | 859.52 | 1,291 | 7.98 | 489.74 | 1,160 | Upgrade
|
| EBIT Margin | 8.46% | 9.68% | 13.77% | 0.10% | 6.03% | 12.71% | Upgrade
|
| Effective Tax Rate | 21.26% | 20.12% | 15.84% | 23.81% | 26.21% | 23.32% | Upgrade
|
| Revenue as Reported | 8,881 | 8,881 | 9,375 | 7,794 | 8,116 | 9,129 | Upgrade
|
| Advertising Expenses | - | 9.45 | 18.46 | 21.25 | 19.59 | 21.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.